Drugs / Neutral Protamine Hagedorn (NPH) insulin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 3 | NCT01798706 Background | Jun 2013 → Feb 2015 | type 2 diabetes mellitus | Sanofi | Completed | Met primary |
| Phase 3 | NCT00993473 Comparator | Oct 2009 → Mar 2011 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT01648218 Comparator | Aug 2012 → Apr 2013 | — | Vancouver General Hospital | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neutral Protamine Hagedorn (NPH) insulin | “Insulin glargine, neutral protamine hagedorn (NPH) insulin, detemir, lente and ultralente were considered as basal insulin.” NCT01798706 ↗ |
| Known as | Huminsulin Basal | “NPH insulin 100 U/mL commercial (Huminsulin Basal) solution for injection” NCT00993473 ↗ |
| Modality | Protein / enzyme biologic | “NPH human insulin” NCT00993473 ↗ |
| Route | Subcutaneous | “NPH) human insulin given as basal insulin either once or twice per day generally in the morning and /or at bedtime by subcutaneous injection” NCT00993473 ↗ |